Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044538
Status:
COMPLETED
Last Update Posted:
2009-06-22
First Post:
2002-08-30
Brief Title:
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Uncontrolled Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma NSCLC
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lung cancer is among the most common cancers in the world and its incidence continues to increase Chemotherapy for patients with Non-Small Cell Lung Cancer NSCLC has been under investigation for several decades and several new drugs with activity in NSCLC have been identified These include the taxanes which are among the most commonly used class of chemotherapy agents in clinical oncology today The usefulness of the taxanes is limited by the development of tumor resistance to these agents This phase II trial with BAY 59-8862 will be conducted to determine the anti-tumor efficacy of BAY 59-8862 in taxane-resistant NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None